Reproductive endocrinology

Growth hormone therapy is associated with improved uterine dimensions in girls with Turner syndrome prior to oestrogen replacement

Clin Endocrinol (Oxf)Published Cross-sectional study

Authors' conclusion

GH therapy has a stimulatory effect on uterine dimensions in pre-and peripubertal girls with TS. Earlier initiation and longer duration of GH is important in TS girls before ERT.

Study context

Population
Premenarchal girls with Turner syndrome (TS), aged 5–15 years, pubertal stage B1-B3, not having received ERT
Exposure
Growth hormone (GH) recipients vs nonrecipients among girls with TS; TS vs age-matched controls
Outcome
UtVol-SDS in girls with TS
Methodological detailsage-matched healthy controls
  • Age-matched healthy controls

Main finding

As reported in the abstract

GH recipients

−0.63

Nonrecipients

−1.39

P = 0.0001

UtL-SDS higher in GH recipients vs nonrecipients (−1.73 vs. −6.49)
P < 0.0001
GH use independently predicted normal uterine volume for age (NUVA) (adjusted for pubertal status, karyotype and height-SDS), OR
5.09 (CI 1.63-15.94; p = .005)

Observational data: associations, not effects.

Further findings

Median UtVol-SDS, UtL-SDS and MOV-SDS, TS vs age-matched controls

UtVol-SDS, TS vs controls (p < .001)
−1.07 vs. 0.86
UtL-SDS, TS vs controls (p < .001)
−3.72 vs. −0.41
MOV-SDS, TS vs controls (p < .001)
−5.53 vs. 1.96

GH initiation and duration, NUVA (n = 29) vs low uterine volume (UtVol) for age (n = 44)

Age at GH initiation, NUVA vs low UtVol (earlier with NUVA; p = .03)
7.8 vs. 9.3 years
Duration of GH, NUVA vs low UtVol (longer with NUVA; p = .002)
3.71 vs. 2.14 years

Correlations of UtVol-SDS with GH

With duration of GH (p = .01)
ρ = 0.411
With age at GH initiation (p = .003)
ρ = −0.479

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Growth hormone therapy is associated with improved uterine dimensions in girls with Turner syndrome prior to oestrogen replacement. Clin Endocrinol (Oxf). Published 9 August 2023. doi:10.1111/cen.14957

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.